Temporary Pause In US Shipments From Sun Pharma's Plant In Mohali
Listen to This Article
United States Food and Drug Administration (USFDA) has asked Sun Pharmaceutical Industries to take certain corrective actions at the Mohali facility before releasing further final product batches into the US, the company said in the notification to the BSE on Sunday.
"The company is taking the required corrective steps, but there will be a temporary pause in the release of batches from Mohali until USFDA-mandated measures are implemented," Sun Pharma said.
US shipments from Mohali will resume once these measures are in place, it added.
Corrective actions include retaining an independent current good manufacturing practice (CGMP) expert to conduct batch certifications of drugs manufactured at the Mohali facility.
Sun Pharma got a consent decree correspondence/non-compliance letter from the US Food and Drug Administration for Mohali Facility.
The consent decree sets a strict timetable and requirements for the firm to ensure it obtains compliance with current good manufacturing practice (CGMP) requirements under the Federal Food, Drug, and Cosmetics Act (FD&C Act).
The facility at Mohali, Punjab was inspected from August 3 to August 12, 2022, and the USFDA classified the inspection as 'Official Action Indicated' (OAI).
“We now wish to inform you that the Company has received a letter titled 'Consent Decree correspondence/non-compliance letter’ from the US FDA. US FDA has directed the Company to take certain corrective actions at the Mohali facility before releasing further final product batches into the US,” Sun Pharma said.
The plant was under OAI status already, which is expected to impact approvals pending for products, but does not impact the current business from the facility. Last November, Sun Pharma had said that the OAI status is not likely to have any material adverse impact on the current business from the facility. It continued to manufacture and distribute existing products for the US market.
HSBC Swings The Axe At UK Wealth In An AI Push
HSBC is preparing deep job cuts across its UK wealth management arm. It plans to cut about half of its management and sp... Read more
Kraken's Owner Buys A Bank: The Lines Are Blurring
Payward, the parent company of the crypto exchange Kraken, has agreed to buy a European bank. It would be the first digi... Read more
Revoluts Australian Banking Licence Game Changer
Revolut has spent much of its life insisting that it is more than a bank. In Australia, it has now decided that becoming... Read more
The AI Bank Is Coming, But Who Controls The Risk?
Artificial intelligence is no longer something banks discuss as a distant possibility. It is already working behind the ... Read more
ClearBank UK Profit Leads To European Growth
ClearBank has spent much of the past decade building the technology and regulatory infrastructure needed to challenge so... Read more